Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Free Report) hit a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $63.97 and last traded at $63.4950, with a volume of 759374 shares trading hands. The stock had previously closed at $60.54.
Analysts Set New Price Targets
Several research firms recently commented on XENE. Bank of America reaffirmed a “buy” rating on shares of Xenon Pharmaceuticals in a report on Monday, March 9th. Wedbush dropped their price objective on shares of Xenon Pharmaceuticals from $64.00 to $63.00 and set an “outperform” rating on the stock in a research note on Monday, March 16th. Royal Bank Of Canada lifted their target price on shares of Xenon Pharmaceuticals from $80.00 to $82.00 and gave the company an “outperform” rating in a report on Friday, May 8th. Robert W. Baird boosted their target price on shares of Xenon Pharmaceuticals from $63.00 to $97.00 and gave the company an “outperform” rating in a research note on Monday, March 9th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Xenon Pharmaceuticals in a report on Wednesday, April 8th. Two analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Xenon Pharmaceuticals has a consensus rating of “Buy” and an average price target of $77.20.
Check Out Our Latest Stock Analysis on XENE
Xenon Pharmaceuticals Price Performance
Xenon Pharmaceuticals (NASDAQ:XENE – Get Free Report) last posted its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($1.17) EPS for the quarter, meeting the consensus estimate of ($1.17). During the same period last year, the company earned ($0.83) earnings per share. On average, research analysts anticipate that Xenon Pharmaceuticals Inc. will post -4.92 earnings per share for the current fiscal year.
Insider Activity
In related news, Director Gillian Cannon sold 1,190 shares of the business’s stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $53.14, for a total transaction of $63,236.60. Following the transaction, the director directly owned 1,455 shares in the company, valued at approximately $77,318.70. The trade was a 44.99% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Gary Patou sold 1,322 shares of the company’s stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $53.14, for a total transaction of $70,251.08. Following the sale, the director directly owned 24,896 shares of the company’s stock, valued at approximately $1,322,973.44. This represents a 5.04% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 4.07% of the company’s stock.
Hedge Funds Weigh In On Xenon Pharmaceuticals
A number of institutional investors have recently added to or reduced their stakes in XENE. Danske Bank A S acquired a new stake in shares of Xenon Pharmaceuticals in the 3rd quarter worth $32,000. Blue Trust Inc. grew its holdings in shares of Xenon Pharmaceuticals by 2,560.7% in the fourth quarter. Blue Trust Inc. now owns 745 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 717 shares during the period. Kestra Advisory Services LLC acquired a new stake in Xenon Pharmaceuticals during the fourth quarter worth about $33,000. Osaic Holdings Inc. raised its stake in Xenon Pharmaceuticals by 541.4% during the second quarter. Osaic Holdings Inc. now owns 1,225 shares of the biopharmaceutical company’s stock worth $40,000 after purchasing an additional 1,034 shares during the period. Finally, Caitong International Asset Management Co. Ltd acquired a new position in Xenon Pharmaceuticals in the 4th quarter valued at about $43,000. Hedge funds and other institutional investors own 95.45% of the company’s stock.
Xenon Pharmaceuticals Company Profile
Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.
The company’s pipeline comprises multiple preclinical and clinical programs.
Featured Articles
- Five stocks we like better than Xenon Pharmaceuticals
- SK Hynix’s Nasdaq Listing Could Reset the AI Memory Trade
- The AI Chip Sell-Off Looks Scary, But the Real Story May Be Liquidity
- Palantir’s CEO Just Called Out OpenAI and Anthropic
- Abivax: Wall Street Catches Up to the Data
Receive News & Ratings for Xenon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
